The phosphatidylinositol-3 kinase (PI-3K) pathway has crucial roles in breast cancer [2], and can be altered at multiple levels, including mutations of the PI-3K catalytic subunit [3] or of its "upstream" or "downstream" regulator/effectors such as PTEN and AKT [4,5]. The gene discussed is AKT1; the disease is breast carcinoma.